GlassScriptPhysician profile
Brad T Pfau
NPI 1992740088
$4,592.92
in general payments reported to CMS, 2019-2025
27 companies · $1,074 in 2025
The $1,074 reported for 2025 was more than what 98% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $409 · 2020: $117 · 2022: $527 · 2023: $1,367 · 2024: $1,100 · 2025: $1,074.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,541.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,540.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $887.87 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $559.08 | 2022-2025 | Qelbree, Qelbree, Oxtellar Xr |
| Neos Therapeutics, LP | $404.73 | 2019-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Merck Sharp & Dohme LLC | $326.11 | 2019-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Ironshore Pharmaceuticals INC. | $311.62 | 2019-2024 | Jornay Pm |
| Glaxosmithkline, LLC. | $285.29 | 2019-2025 | Bexsero, Pediarix, Penmenvy |
| Collegium Pharmaceutical, INC. | $255.99 | 2025 | Jornay Pm |
| Pfizer INC. | $252.96 | 2019-2025 | |
| Seqirus USA INC | $207.75 | 2022-2025 | Flucelvax, Flucelvax Quadrivalent |
| Neurelis, INC. | $181.79 | 2024-2025 | Valtoco |
| Vertical Pharmaceuticals, LLC | $127.38 | 2019-2025 | Relexxii |
| Cranial Technologies, INC | $99.70 | 2019-2025 | Doc Band |
| Kaleo, INC. | $96.80 | 2019-2023 | Auvi-Q |
| Sanofi-Aventis U.S. LLC | $95.42 | 2024-2025 | |
| Tris Pharma INC | $87.12 | 2019-2024 | Dyanavel Xr |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $72.95 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $69.49 | 2023-2024 | Flumist Quadrivalent |
| Sanofi Pasteur INC. | $58.85 | 2019-2023 | |
| Noven Therapeutics, LLC | $54.90 | 2023-2024 | Xelstrym |
| Philips North America LLC | $30.62 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $27.14 | 2025 | Zoryve |
| Rhodes Pharmaceuticals L.P. | $23.55 | 2019 | |
| Organon LLC | $17.38 | 2025 | |
| Phadia US INC. | $15.71 | 2022 | |
| Acadia Pharmaceuticals INC | $15.57 | 2025 | Daybue |
| Ars Pharmaceuticals Operations, INC. | $15.57 | 2025 | Neffy |
| Sobi, INC | $11.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brad Pfau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.